Patents Assigned to ULTIMORPHIX TECHNOLOGIES B.V.
  • WET GRANULATION OF TENOFOVIR, EMTRICITABINE AND EFAVIRENZ
    Publication number: 20110288045
    Abstract: The present invention describes a method and composition for a pharmaceutical product based on Tenofovir disoproxil hemifumarate, Emtricitabine and Efavirenz. The composition can be prepared by a process comprising a wet granulation step to produce a stable dosage form suitable for the treatment of HIV in essential absence of known degradation products.
    Type: Application
    Filed: November 19, 2009
    Publication date: November 24, 2011
    Applicant: ULTIMORPHIX TECHNOLOGIES B.V.
    Inventors: Rita Ramos, Evanthia Dova, Samir Kulkarni, Marcel Hoffmann
  • SOLID FORMS OF TENOFOVIR DISOPROXIL
    Publication number: 20110009368
    Abstract: The Present Invention Provides Tenofovir Disoproxil Succinate, Tenofovir Disoproxil L-Tartrate, Tenofovir Disoproxil oxalate, Tenofovir disoproxil saccharate, Tenofovir disoproxil citrate, Tenofovir disoproxil salicylate and various solid forms thereof, methods for the preparation thereof and their use in pharmaceutical applications, in particular in anti-HIV medicaments. The forms of Tenofovir disoproxil can be used in combination with other anti-HIV medicaments such as Efavirenz and Emtricitabine.
    Type: Application
    Filed: December 11, 2008
    Publication date: January 13, 2011
    Applicant: ULTIMORPHIX TECHNOLOGIES B.V.
    Inventor: Evanthia Dova
  • Tenofovir Disoproxil Hemi-Fumaric Acid Co-Crystal
    Publication number: 20090270352
    Abstract: The present invention provides a novel crystalline form of Tenofovir disoproxil fumarate (Tenofovir DF), designated Co-crystal TDFA 2:1, methods for the preparation thereof and its use in pharmaceutical applications, in particular in anti-HIV medicaments. The crystalline form TDFA 2:1 can be used in combination with other anti-HIV medicaments such as Efavirenz, Emtricitabine, Ritonavir and/or TMC114.
    Type: Application
    Filed: May 21, 2008
    Publication date: October 29, 2009
    Applicant: ULTIMORPHIX TECHNOLOGIES B.V.
    Inventors: Evanthia Dova, Jaroslaw Marek Mazurek, Johnny Anker
  • Tenofovir Disoproxil Hemi-Fumaric Acid Co-Crystal
    Publication number: 20090176983
    Abstract: The present invention provides a novel crystalline form of Tenofovir disoproxil fumarate (Tenofovir DF), designated Co-crystal TDFA 2:1, methods for the preparation thereof and its use in pharmaceutical applications, in particular in anti-HIV medicaments. The crystalline form TDFA 2:1 can be used in combination with other anti-HIV medicaments such as Efavirenz, Emtricitabine, Ritonavir and/or TMC114.
    Type: Application
    Filed: December 1, 2008
    Publication date: July 9, 2009
    Applicant: ULTIMORPHIX TECHNOLOGIES B.V.
    Inventors: Evanthia Dova, Jaroslaw Marek Mazurek, Johnny Anker